Introduction
Chronic lower respiratory diseases such as chronic obstructive pulmonary disease (COPD) represent a substantial portion of the burden of chronic illness in the United States (US). In 2008, chronic lower respiratory diseases surpassed stroke to become the third leading cause of death in the US, 1 and the US ranked second highest in COPD mortality in 2007 compared with 16 industrialized countries. 2 Projections suggest that the global ranking of COPD mortality will rise relative to other causes over the next 20 years. 3 In a study of chronic diseases among Medicare beneficiaries in 2005, patients with evidence of COPD comprised a greater proportion of the population than patients with cancer (breast, colorectal, prostate, and lung cancer combined) or chronic kidney disease. 4 COPD is a progressive respiratory disease defined by airflow limitation. 5 The working definition set forth by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) states: "COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases." 5 In addition to these defining characteristics, patients also exhibit chronic dyspnea and bronchitis, cough, sputum production, and pathologic features of emphysema. Patients with moderate to severe COPD have periods of symptom worsening superimposed on overall disease progression. These exacerbations negatively affect patient quality of life. 6, 7 Aims of managing stable COPD include reducing the frequency and severity of exacerbations as well as controlling baseline symptoms. 5, 8, 9 Maintenance medications, including bronchodilators, inhaled corticosteroids, combination medications, and oxygen therapy for severe COPD are primarily used at home. Hospitalization is common for patients experiencing a severe exacerbation. 5, 10, 11 Severe exacerbations might be managed in an inpatient or emergency department (ED) setting, but life-threatening exacerbations may require immediate intensive care unit (ICU) admission. 5 The high prevalence 2,3,12-14 and morbidity of COPD contributed to a projected US$29.5 billion in related direct costs in 2010 in the US. 2 In an analysis of commercially insured patients in the US in 2006, the mean annual COPDrelated health care cost per patient was estimated to range from US$2003 to US$43,461 (2008 cost year), depending on the level of care received. 15 Mean hospital costs for visits associated with exacerbations in 2008 were estimated to range up to US$44,909 for ICU admissions that required intubation; this value increased to US$45,607 when only Medicare beneficiaries were included in the analysis. 16, 17 In a study of Medicare beneficiaries in 2005, the mean annual payment per patient with COPD, estimated as US$21,409, exceeded average payments for patients with heart failure, depression, cancer, or diabetes. 4 This study of Medicare costs covered a period prior to the implementation of the Part D pharmacy benefit, and thus does not reflect pharmacy costs.
Hospitalization is a significant aspect of the burden of COPD. US national survey data indicate that hospitalizations for COPD have increased since 1990, reaching 23.6 per 10,000 population in 2005. 18 Discharge data from US hospitals in 2007 showed that COPD accounted for 26.1 hospitalizations per 10,000 population aged 45-64 years; this rate was similar to that reported for diabetes and pneumonia in this age group. 19 For patients aged 65-74 years, however, the hospitalization rate for COPD more than tripled to 92.6 per 10,000 populationsimilar to pneumonia but exceeding diabetes in this age group. 19 In addition, Medicare beneficiaries with COPD had more inpatient stays and days than patients with cancer, diabetes, or heart failure in 2005. 4 Hospitalization is a major cost driver in COPD management overall 2, 15, 20 and is a primary component of exacerbation costs. 21 Hospital care was projected to account for 45% of direct COPD costs in the US in 2010, whereas prescription drugs comprised approximately 20%.
2 Inpatient care accounted for approximately 80% of excess costs for COPD patients in a matched comparison of Medicare beneficiaries with and without COPD in 2004. 22 Because of the link between exacerbations and hospitalization, reducing exacerbation frequency or severity could reduce COPDrelated hospitalizations and thereby reduce costs. 23, 24 Disease-management initiatives have potential to reduce health care costs associated with COPD. 25 In order to assess the effect of such initiatives, a benchmark is needed for comparison. The objectives of this study are to provide a baseline estimate of costs of COPD-related care for patients in the US, including those on Medicare Advantage plus Part D or with commercial insurance, and to assess cost trends over time.
Material and methods

Data source
Medical, pharmacy, and enrolment data from a large US health care claims database affiliated with OptumInsight (formerly Innovus) were used in this retrospective study. ie, individual patients were not followed longitudinally from year to year although they may have been included in more than 1 year-based cohort if they fulfilled the inclusion criteria in more than 1 year.
Data regarding patient characteristics were collected from enrolment information and claims. These included age, sex, geographic region, and evidence of comorbidities such as asthma. Diagnosis of asthma (ICD-9-CM 493.xx), chronic bronchitis (491.xx), emphysema (492.xx), or chronic airway obstruction not elsewhere classified (496.xx) in any position during the year was noted, and comorbidity burden was quantified using the Quan-Charlson comorbidity score. 27 
Cost calculations
COPD-related costs were tabulated in each year of interest based on total paid amounts, including patient-and health plan-paid amounts. Use of actual paid costs provides a view of the true costs of COPD incurred by payers and patients.
Costs for commercially insured patients include estimated Medicare or other payer contributions based on coordination of benefits information. All costs were adjusted to 2008 US dollars using the Consumer Price Index. 28 Medical costs comprise costs for COPD-related visits, other related medical services (ie, from claims with COPD diagnosis in the primary position that did not fall into specified visit categories), and oxygen use. COPD-related visits included outpatient, urgent outpatient, and ED visits, as well as standard admissions (no ICU) and ICU stays. An "outpatient" visit was defined as a medical claim for office or outpatient care with COPD indicated in the primary or secondary position, but no evidence of an "urgent" visit (defined below). Outpatient care included physician office visits, outpatient hospital services, laboratory visits, and urgent care center visits. An "urgent outpatient" visit was based on a medical claim for outpatient care for COPD (primary or secondary position) followed by a pharmacy claim for an oral corticosteroid or antibiotic within 7 days after the visit. An "ED" visit was based on a medical claim for an ED visit for COPD (primary position). A "standard admission" was based on an inpatient stay for COPD (diagnosis in the primary position on a hospital claim), but no evidence of ICU treatment during the stay. "ICU" care was defined as a medical claim during an inpatient stay with revenue code of 020x, 021x, 0223, or 0234 or a current procedural terminology (CPT) procedure code for critical care (99291-99292). Oxygen use was identified by medical procedure (CPT/HCPCS E0424-E0444, E0445, E0455, E0550, E0560, E1353-E1372, E1399, K0740; ICD-9 93.96), diagnosis (ICD-9 V46.2), and facility revenue codes (0277, 0544, 060x).
COPD-related pharmacy costs were summed from pharmacy claims for any of the following medications: short-acting beta agonists, LABAs, anticholinergics, methylxanthines, oral/intravenous corticosteroids, inhaled corticosteroids, inhaled corticosteroid/LABA combinations, other respiratory medications, or antibiotics.
Patient-and visit-level analyses
Patient-level costs were calculated as the sum of costs during the year of interest and reported as the mean annual cost among patients in the year-based cohort. COPD-related medical and pharmacy costs are reported separately in the patient-level analysis, and total COPD-related health care costs are the sum of COPD-related medical and pharmacy costs. Visit-level costs were calculated based on all visits of a given type during the year and are reported as the mean cost per COPD-related care submit your manuscript | www.dovepress.com
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episode. Multivariate models were used to assess patient-level and visit-level cost trends over time.
COPD-related hospital readmissions were also assessed. COPD-related readmissions were defined as COPD-related hospital stays (primary diagnosis of COPD) that occurred after the initial COPD-related admission (ie, patients who had more than one COPD-related hospital stay in the study year were considered to have a readmission). The percentages of patients with readmissions within 30 days and 60 days of the initial admission are also reported. ED visits were not considered in the assessment of readmissions.
Statistical analysis
Patient-and visit-level costs are reported with descriptive statistics. Trends over time were investigated with generalized linear models with gamma distribution and log link to account for the skewed distribution of costs. 29 The models adjusted for sex, age category, and geographic region, with year as the primary predictor. The models did not adjust for comorbidity because changes in costs for COPD care year over year might be related to management of associated comorbid conditions. The authors did not want to "control away" differences in comorbid status that are clinically associated with COPD. A threshold of P , 0.05 was used to define statistical significance. The multivariate models were fit by Stata 10.0 (StataCorp, College Station, TX) software, and all other analyses were conducted using SAS ® 9.1 (SAS Institute, Cary, NC).
Results
Patient characteristics
Demographics and comorbidities of the commercial and Medicare Advantage COPD patient cohorts in 2009 are shown in Table 1 . Characteristics of the patient cohorts from years 2006 through 2008 are shown in Appendix 1. Across each year studied, demographic characteristics of commercial cohorts were similar to each other and characteristics of Medicare Advantage cohorts were similar to each other. The highest proportion of patients was from the South region for all commercial and Medicare Advantage cohorts, which reflects the distribution of patients in the overall database population. In each year studied, the mean age of the Medicare Advantage cohort was approximately 10 years older than that of the commercial cohort, as expected. Within each year, the proportions of patients with the respiratory comorbidities noted in Table 1 
Patient-level costs of COPD
Mean annual COPD-related health care costs for each commercial insurance and Medicare Advantage cohort are shown in Figure 1 . Medical costs, which comprise amounts paid for facility and physician services, accounted for the majority of total costs in all cohorts. COPD-related medical costs were approximately 16%-19% lower for Medicare than commercial cohorts, and total costs were approximately 7%-10% lower for Medicare than commercial cohorts in each year that both insurance types were studied.
Based on the multivariate analysis, total costs increased over time for both Medicare Advantage and commercial insurance patients after adjustment for age, sex, and region. The rate of increase for total costs was approximately 6% per year for commercial insurance patients and 5% per year for Medicare Advantage patients (Table 2) . Both pharmacy and medical costs increased significantly over time for the commercial population, but only medical costs increased significantly for the Medicare Advantage population (Table 2 ). 
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Pharmacy costs accounted for a small proportion of total COPD costs for both cohorts. 
Visit-level costs of COPD
Mean costs of nonhospital COPD-related visits by year and insurance type are shown in Figure 2 , and costs of standard admissions and ICU visits are shown in Figure 3 . Commercially insured patients accounted for greater costs than Medicare Advantage patients for ambulatory visits, standard admissions, and ICU care, whereas Medicare patients accounted for greater ED costs than commercial patients. Cost values are shown in Appendix 2.
After adjustment for age, sex, and region; costs for outpatient, urgent outpatient, and ED visits increased significantly over time in both populations ( Table 2 ). The rate of increase for outpatient visit costs was approximately 6% per year for commercial patients, but only 2% per year for Medicare Advantage patients (Table 2) . Costs for standard admissions increased significantly over time for patients with Medicare, but not for those with commercial insurance, and costs for ICU care remained stable for both populations. 
COPD readmissions
Among patients with a standard admission or ICU stay 16 Relative to 2005, hospital costs for a standard admission were 6%-11% higher and ED costs were 4%-10% higher over the period 2006 through 2008, but a consistent upward trend was not evident. 16 Hospital costs for encounters with ICU or intubation varied by less than 3% from 2005 through 2008, 16 which is consistent with the findings of this present study that total payer-and patient-paid ICU costs did not increase significantly over the studied period. Notwithstanding this lack of increase, ICU stays were expensive for both the commercial and Medicare Advantage populations. ICU visit costs for commercially insured patients were more than double the costs for patients on Medicare Advantage. Possible reasons for this discrepancy include Medicare cost control and the difference in age between the populations. The commercial patients were younger on average, and it is possible that younger patients receive more aggressive or costly care independent of insurance type. However, this study did not address these possible explanations and additional research is needed.
It would be of interest to compare costs between Medicare and commercial enrollees aged 65 and older, but cost differences are difficult to parse out due to differences in the populations as well as because of how costs are calculated. The age 65 and older commercial population consists of patients still working, retirees, and patients with spouses who retain commercial insurance. Because commercial benefits are coordinated with Medicare, costs (primarily for hospitalization services, but in some cases for Part B services) are necessarily calculated using an estimator of the contribution of Medicare to paid amounts. Addressing this complex issue was beyond the scope of the study.
The data provide a benchmark for assessing the impact of changes in COPD management practices. Because ICU stays and hospitalizations for patients with COPD can often be the result of exacerbations, reducing the frequency of severe exacerbations could help to control COPD-related costs. Treatments that reduce the frequency of COPD-related hospitalizations or exacerbations 11 are also associated with lower COPD-related medical costs, and in some cases lower total COPD-related costs. 30, 31 Additional research is needed to investigate the interrelationships among treatment for COPD, risk of exacerbation and hospitalization, and costs.
Like previous studies, patients in this present analysis had a high rate of readmissions, and many of these visits occurred within a month of the index visit. An analysis of Medicare claims from 2003 through 2004 reported a readmission rate of 23% for patients with an initial admission for COPD. 32 Patients with an initial COPD-related admission accounted for 4% of all rehospitalizations observed in that study, and COPD was the third most common index condition associated with rehospitalization, after heart failure and pneumonia. 32 Records from five New York City hospitals indicate that 22% of hospitalizations for COPD exacerbations in a 2-year period are repeat admissions; 17.6% of patients are readmitted at least once. 33 Hospital data from 2008 indicate that between 15% and 18% of patients with an initial ED or inpatient visit for COPD have a repeat visit within 60 days. 16, 17 Given the high rate of hospitalization of patients with COPD, interventions aimed at reducing the need for COPD-related admissions and readmissions may help to lessen resource use and costs for this patient population.
Like all retrospective claims-based studies, this study is limited by constraints of the data source, and results must be interpreted in the context of these limitations. Claims are collected for payment, not research, and coding errors are possible. Although this present analysis included only direct costs, indirect costs of COPD are also substantial, 2,23,34 and the results of this present study are likely to underestimate the overall burden of COPD. Clinical measures of COPD severity were not available in the dataset, and thus the influence of severity on annual or visit costs could not be determined. The results might not generalize to uninsured patients or patients in areas with limited access to medical care. Finally, each calendar yearbased cohort was identified separately -patients were not examined longitudinally -and there is overlap between cohorts from year to year.
Conclusion
The economic burden of COPD on patients and payers grew from 2006 through 2009, and much of these costs are attributable to medical expenses. This information can be used to evaluate the effect of changes in the practice of COPD management. Improved symptom management could reduce demand for high-cost medical resources, such as ICU care, and reduce overall COPD-related costs.
